AOD-9604 Research Compound
Research Use Only
This product is intended for laboratory research purposes only. It is not intended for human or veterinary use, food, cosmetic, household, or agricultural applications. Not for human consumption.
Overview
AOD-9604 (Anti-Obesity Drug-9604) is a synthetic peptide fragment corresponding to the C-terminal portion of human growth hormone (amino acids 176-191). Developed by Metabolic Pharmaceuticals, this modified fragment was designed to retain the fat-reducing properties of HGH while eliminating its growth-promoting and diabetogenic effects. Although clinical trials for obesity treatment did not meet primary endpoints, AOD-9604 remains an active research compound for studying fat metabolism mechanisms.
Molecular Characteristics
| Property | Value |
|---|---|
| Molecular Formula | C78H123N23O23S2 |
| Molecular Weight | 1815.08 g/mol |
| CAS Number | 221231-10-3 |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe |
| Amino Acids | 16 |
| Structure | Contains disulfide bridge (Cys⁷-Cys¹⁴) |
| Purity | ≥99% (HPLC) |
Mechanism of Action
AOD-9604 affects lipid metabolism through specific pathways:
Lipolytic Activity
- Stimulation of lipolysis in adipose tissue
- Activation of beta-3 adrenergic receptors
- Hormone-sensitive lipase (HSL) activation
- Free fatty acid release enhancement
Anti-Lipogenic Effects
- Inhibition of lipogenesis
- Reduction of fat accumulation
- Modulation of fatty acid synthase
- Altered adipocyte metabolism
Distinct from Full HGH
- No IGF-1 elevation
- No hyperglycemic effects
- No growth promotion
- Limited to C-terminal region activity
Potential Additional Effects
- Cartilage regeneration research
- Osteoarthritis models
- Tissue repair studies
Research Applications
Adipose Tissue Research
- Lipolysis mechanism studies
- Adipocyte function research
- Fat depot differences
- Obesity models
Metabolic Studies
- Energy expenditure research
- Substrate oxidation
- Metabolic rate assessment
- Insulin sensitivity effects
Body Composition
- Fat mass reduction models
- Lean mass preservation studies
- Regional fat distribution
- Long-term effects
Cartilage/Joint Research
- Chondrocyte studies (GRAS status in Australia)
- Osteoarthritis models
- Cartilage repair mechanisms
Available Formats
| Size | Format | Catalog Code |
|---|---|---|
| 2mg | Lyophilized | AOD-2 |
| 5mg | Lyophilized | AOD-5 |
| 10mg | Lyophilized | AOD-10 |
Handling & Storage
- Store lyophilized peptide at -20°C
- Protect from light and moisture
- Reconstitute with bacteriostatic water
- Reconstituted solution stable at 2-8°C for up to 3 weeks
- Contains disulfide bridge (avoid reducing agents)
- Avoid repeated freeze-thaw cycles
Quality Specifications
- Purity: ≥99% by HPLC
- Appearance: White lyophilized powder
- Solubility: Soluble in water
- Disulfide Bridge: Intact (verified)
- Endotoxin: Less than 1 EU/mg
- Certificate of Analysis provided
Clinical Trial History
| Phase | Outcome |
|---|---|
| Phase I | Safety established |
| Phase IIa | Positive signals |
| Phase IIb/III | Did not meet primary endpoint for obesity |
| Current | Research continues; GRAS for joint health (Australia) |
References
- Heffernan MA, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and rats." Endocrinology. 2001.
- Ng FM, et al. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Horm Res. 2000.
- Stier H, et al. "AOD9604, a synthetic C-terminal fragment of human growth hormone: a phase II study in obese patients." Int J Obes. 2008.